Martin H Goldberg

7115607, Oct 3, 2006

Jul 24, 2002

10/202823

Christopher H. Fotsch - Thousand Oaks CA, US
Premilla Arasasingham - Thousand Oaks CA, US
Yunxin Bo - Thousand Oaks CA, US
Ning Chen - Thousand Oaks CA, US
Martin H. Goldberg - Woodland Hills CA, US
Nianhe Han - Thousand Oaks CA, US
Feng-Yin Hsieh - Thousand Oaks CA, US
Michael G. Kelly - Thousand Oaks CA, US
Qingyian Liu - Camarillo CA, US
Mark H. Norman - Thousand Oaks CA, US
Duncan M. Smith - Thousand Oaks CA, US
Markian Stec - Fillmore CA, US
Nuria Tamayo - Newbury Park CA, US
Ning Xi - Thousand Oaks CA, US
Shimin Xu - Moorpark CA, US

Amgen Inc. - Thousand Oaks CA

A61K 31/496
C07D 401/12
C07D 403/12

51425213, 51425305, 51425306, 51425313, 51425409, 544359, 544363, 544365, 544373, 544376, 544379

Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

20040254178, Dec 16, 2004

Apr 15, 2004

10/826982

Celia Dominguez - Thousand Oaks CA, US
Martin Goldberg - Woodland Hills CA, US
Nuria Tamayo - Newbury Park CA, US

Amgen Inc.

C07D417/02
C07D413/02
C 07D 4 3/02

514/227500, 514/235200, 514/235500, 514/252030, 514/253050, 514/341000, 514/340000, 544/060000, 544/124000, 544/238000, 544/360000, 546/268100

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

20050038010, Feb 17, 2005

May 13, 2003

10/438553

Guo-Qiang Cao - Thousand Oaks CA, US
Celia Dominguez - Thousand Oaks CA, US
Martin Goldberg - Woodland Hills CA, US
Kelvin Sham - Thousand Oaks CA, US
Seifu Tadesse - Simi Valley CA, US
Nuria Tamayo - Newbury Park CA, US
Kurt Weiler - Thousand Oaks CA, US
Dawei Zhang - Thousand Oaks CA, US
Hongyu Liao - Thousand Oaks CA, US

A61K031/553
A61K031/55
A61K031/541
A61K031/5377
A61K031/496
A61K031/497

514211150, 514217050, 514227800, 514235500, 514242000, 514252020, 514252030, 514252050, 514255050, 514256000, 540598000, 540488000, 544060000, 544112000, 544122000, 544295000, 544331000, 544238000, 544405000

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein Ris a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein Ris additionally substituted; and Ris a substituted Calkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

20070265248, Nov 15, 2007

Apr 27, 2005

11/116759

Christopher Fotsch - Thousand Oaks CA, US
Premilla Arasasingham - Thousand Oaks CA, US
Yunxin Bo - Thousand Oaks CA, US
Ning Chen - Thousand Oaks CA, US
Martin Goldberg - Woodland Hills CA, US
Nianhe Han - Thousand Oaks CA, US
Feng-Yin Hsieh - Thousand Oaks CA, US
Michael Kelly - South San Francisco CA, US
Qingyian Liu - Camarillo CA, US
Mark Norman - Thousand Oaks CA, US
Duncan Smith - Thousand Oaks CA, US
Markian Stec - Fillmore CA, US
Nuria Tamayo - Newbury Park CA, US
Ning Xi - Thousand Oaks CA, US
Shimin Xu - Santa Barbara CA, US
Elizabeth Doherty - Newbury Park CA, US

Amgen Inc. - Thousand Oaks CA

A61K 31/4965
A61K 31/497
A61K 31/551
A61P 3/10
C07D 243/08
C07D 401/00
C07D 403/12
C07D 407/00

514218000, 514252130, 514253010, 514253060, 514254050, 514254090, 514254110, 514255010, 540575000, 544359000, 544360000, 544363000, 544370000, 544373000, 544377000, 544386000

Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.